While we have numerous symptomatic treatments today, there is still no cure for neurodegenerative diseases such as Parkinson’s and Alzheimer’s. There are more than 600 neurodegenerative diseases alone that affect the brain, spine, and peripheral nervous system. While diseases like Parkinson’s affect motor functions, Alzheimer’s is a progressive disease that destroys memory and other mental functions.
Celebrating Thirty Years of Good Laboratory Practice
The GLP (Good Laboratory Practice) Testing Facility of Eurofins Central Laboratory in Breda, The Netherlands has been accredited for OECD GLP for over 30 years. It all started at the BCO Centre for Research (B for Bergschot 71, the street address ever since) with the first inspection by the Dutch Health Care Inspectorate in June 1988. Over the years, BCO underwent several transformations and evolved into becoming one of the Eurofins Central Laboratory facilities, keeping the GLP Test Facility embedded in the Breda Clinical Laboratory.
Currently, there aren't any globally-approved pharmaceutical treatments for Stress Urinary Incontinence (SUI). With a predominately female patient population ranging in the hundreds of millions of people worldwide, this provides them with only surgical and physical therapy-based options, limiting their choice of solutions. While effective for some, there can be challenges that come with the invasive nature of surgical procedures, as well as non-compliance with the length of time required for successful physical therapy outcomes.
On November 17th, 2018, we celebrate World Prematurity Day with March of Dimes. According to March of Dimes, "Premature birth is the leading cause of death in children under the age of five worldwide. Babies born too early may have more health issues than babies born on time, and may face long-term health problems that affect the brain, the lungs, hearing or vision."